BEIJING (Reuters) – Various efficacy results for Chinese COVID-19 vaccine released separately in China and the UAE are both true and valid, said a senior official at China National Biotec Group (CNBG) ) to the state media.
China approved its first COVID-19 vaccine for general public use on Thursday, a bullet developed by a state-backed Sinopharm relative, after the developer said the vaccine showed a 79.34% established efficacy on an interim study of late-stage clinical trials.
That rate is lower than the 86% rate for the same vaccine reported by the United Arab Emirates on December 9.
Countries differ significantly in their standards and procedures in patient experience, and the final results of COVID-19 case identification were different, said Yang Xiaoming, chairman of CNBG Sinopharm unit, to Global Times, a tabloid published by the People’s Daily, the official newspaper. Communist Party of China’s ruling.
“Therefore, there were discrepancies between the complete multinational data we reviewed and the protection level data previously assessed by the UAE and Bahrain,” Yang Times said in a report that was announced Thursday.
“But both of those results are true and valid,” Yang said, without offering further details for the data.
CNBG did not participate in a study or review of clinical trial data released by regulators in countries where its vaccine was being tested, Yang said.
The vaccine, developed by the CNBG unit of the Beijing Institute of Biological Products, together with another candidate from the Wuhan – based unit of CNBG, is being tested in Phase III clinical trials outside China.
Tests for CNBG candidates have hired more than 60,000 participants aged 18-60, Yang said.
Reciting with Roxanne Liu and Ryan Woo; Edited by Kim Coghill